Vibration therapy is a form of treatment during which localised or whole-body vibration is applied to the body of the patient, usually with the use of a vibration-generating device.
The health benefits of vibration are widely known and recognised. Whole-body vibration has shown positive effects in managing life-disrupting symptoms of musculoskeletal and neurodegenerative disorders, in injury rehabilitation and the strengthening of muscle and bone tissues.¹
Localised vibration, a more targeted form of therapy, has shown promising results in the symptomatic treatment of respiratory disorders, chronic wounds and pain arising from the soft tissues.²
The Vibration Therapies platform of SynDermix is based on digital acoustic modulation — precisely controlled vibrational energy from sound — that triggers biological responses on a cellular level in targeted tissues. The non-invasive exposure of impaired tissues to specific frequencies enables cellular recuperation of lost energy, cellular expression of energy, and the proliferation and production of biomolecules that exert therapeutic effects.
SynDermix is working together with Swiss biomedical inventors and engineers to create breakthrough technology in frequency-conducting portable medical devices for localised use. The Company’s goal is to develop handheld, smart devices whose electronic technology, precision and usability are custom-engineered to address the clinical specificities of targeted conditions, and which meet strict regulatory standards.
In parallel, the interaction of the devices with smartphone apps will enable patients to keep track of their treatment regimens and to monitor the frequency of the exacerbations of their conditions with minimum effort.
The most advanced medical device in our vibration therapies pipeline is indicated for the treatment of chronic rhinosinusitis — a condition suffered by an estimated 5–15% of the general population in Europe and the United States alone.³ The device is scheduled to enter into a confirmatory clinical study in October 2019.
Chronic rhinosinusitis (CRS) is an inflammatory disorder of the sinonasal passages whose symptoms last 12 weeks or longer. Symptoms include nasal congestion and/or discharge, facial pain or pressure and loss of smell.
CRS dramatically impacts the quality of life of patients. The disorder is evaluated to be equally or more disruptive than chronic obstructive pulmonary disease, asthma, peptic ulcer disease and congestive heart failure.⁴ Patients can experience multiple acute exacerbations within the span of a year.
SDX-3101 is a non-invasive, painless and drug-free medical device for external use, indicated for the treatment of mild to severe CRS without nasal polyps in adult patients, with or without seasonal exacerbation.
The device is applied to the cheekbone and produces vibrational energy from sound that penetrates through the tissues into the sinonasal cavities and promotes the normalisation of the body’s defences, leveraging the anti-inflammatory, anti-oedematous and anti-allergic effects of vibration therapy.⁵ The device additionally alleviates facial pain associated with CRS.
Going forward, SynDermix intends to leverage its proprietary technology and clinical findings to develop medical devices to treat painful neurological disorders and for wound-healing.